Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer

DNA polymerase mutations can cause hypermutant cancers, but the mechanisms of tumorigenesis and the impact of various DNA polymerase mutations on treatment response is poorly understood. In this issue of Cancer Research, Galati and colleagues investigate the effects of cancer-associated DNA polymerase ε (Pole) mutations on tumorigenesis and response to immune checkpoint blockade. They describe novel genetically engineered mouse models harboring cancer-associated Pole mutations and examine the effects of these mutations on tumorigenesis, the tumor mutational landscape, and the tumor immune microenvironment. Integrating this information with an emerging understanding of how different tumor mutations influence the response to immunotherapy may aid in prediction, diagnosis, and treatment of Pole-mutant tumors. See related article by Galati et al., p. 5606

[1]  C. Hawkins,et al.  Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade , 2020, Cancer Research.

[2]  J. Frank,et al.  Abstract 5606: Characterization of temporal proteomic dynamics of murine breast and melanoma tumor microenvironments without and with pulsed focused ultrasound , 2020 .

[3]  P. Koduru,et al.  A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. , 2020, JCI insight.

[4]  Cierra S. Hong,et al.  A single cell atlas reveals distinct immune landscapes in transplant and primary tumors that determine response or resistance to immunotherapy , 2020, bioRxiv.

[5]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[6]  A. Alice,et al.  Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity , 2018, Scientific Reports.

[7]  K. Cole,et al.  Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.

[8]  R. Rad,et al.  PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis , 2017, Nature.

[9]  B. Vogelstein,et al.  Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention , 2017, Science.

[10]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[11]  R. Goldsby,et al.  DNA polymerase ε and δ proofreading suppress discrete mutator and cancer phenotypes in mice , 2009, Proceedings of the National Academy of Sciences.